Innoviva appoints Dr. Sapna Srivastava to board, effective Jan 1, 2023

Innoviva, Inc.

Dr. Sapna Srivastava appointed to Board as independent director, effective Jan 1, 2023.
Srivastava brings experience as former CFO of Intellia Therapeutics and Abide Therapeutics, and 15 years as biotech analyst.
Received initial RSU award of $125,000, prorated RSU of $56,250, and option for 2,500 shares.
Annual cash retainer of $50,000 for board service.
Bylaws amended to remove reference to SmithKline Beecham and update director nomination procedures.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sapna Srivastava

Director

INVA · Innoviva, Inc.

Effective: 2023-01-01
Filed: January 4, 2023, 6:59 PM ET

On December 29, 2022, Innoviva, Inc. (the “Company”) appointed Sapna Srivastava, Ph. D., to its Board of Directors (the “Board”), effective January 1, 2023 (the “Srivastava Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sapna Srivastava was appointed as Director at Innoviva, Inc..

Action: appointed
Role: Director

Exact text from the filing

On December 29, 2022, Innoviva, Inc. (the “Company”) appointed Sapna Srivastava, Ph. D., to its Board of Directors (the “Board”), effective January 1, 2023 (the “Srivastava Effective Date”).

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Innoviva, Inc.: Amended the Company's by-laws to remove reference to SmithKline Beecham Corporation as a shareholder and update procedures and information requirements for director nominations, including with respect to Rule 14a-19 (effective 2023-01-01).

Change: bylaw amendment
Effective: 2023-01-01

Exact text from the filing

On December 31, 2022, the Board amended the Company’s by-laws, effective as of January 1, 2023, to remove reference to SmithKline Beecham Corporation, a Pennsylvania corporation, as a shareholder of the Company and update the procedures and information requirements for the nomination of directors, including with respect to Rule 14a-19 promulgated under the Securities Exchange Act of 1934, as amended.

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Innoviva, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-000897

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.